

Title (en)
THE USE OF 5 FLUOROURCIL, DELIVERED BY INOTOPHORESIS AS AN INHIBITOR OF CELL PROLIFERATION IN THE EYE, BULBAR AND PALPEBRAL CONJUNCTIVA, EYELID, PERI-ORBITAL SOFT TISSUES AND SKIN

Title (de)
VERWENDUNG VON 5-FLUOROURACIL, VERABREICHT DURCH INOTOPHORESE, ALS HEMMER DER ZELLPROLIFERATION IM AUGE, DER BULBÄREN UND PALPEBRALEN KONJUNKTIVA, DEM AUGENLID, DEM PERIORBITALEN GEWEBEN UND DER HAUT

Title (fr)
UTILISATION DE 5 FLUOROURCIL, ADMINISTRE PAR IONTOPHORESE EN TANT QU'INHIBITEUR DE LA PROLIFERATION CELLULAIRE DANS L'OEIL, LA CONJONCTIVE BULBAIRE ET PALPEBRALE, LA PAUPIERE, LES TISSUS MOUS ET LA PEAU PERIORBITAIRES

Publication
EP 1418919 A4 20070613 (EN)

Application
EP 02747054 A 20020719

Priority
• US 0222860 W 20020719
• US 30678801 P 20010720

Abstract (en)
[origin: WO03007798A2] A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a 5' fluorouracil based medicament, wherein the 5' fluorouracil based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the 5' fluorouracil based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.

IPC 8 full level
A61K 31/513 (2006.01); **C07D 239/553** (2006.01); **A61K 9/08** (2006.01); **A61N 1/30** (2006.01); **A61P 27/02** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)
A61K 31/513 (2013.01); **A61N 1/30** (2013.01); **A61P 27/02** (2017.12); **A61P 35/00** (2017.12)

Citation (search report)
• [XY] WO 9940967 A1 19990819 - HADASIT MED RES SERVICE [IL], et al
• [X] WO 0051620 A1 20000908 - VITREO RETINAL TECHNOLOGIES IN [US]
• [Y] EP 0927560 A1 19990707 - OPTISINVEST [AN]
• [Y] US 5298017 A 19940329 - THEEUWES FELIX [US], et al
• [Y] JP H0549702 A 19930302 - TEIJIN LTD
• [PY] WO 0191853 A1 20011206 - BIOPHORETIC THERAPEUTIC SYSTEM [US]
• [E] WO 03007961 A1 20030130 - IOMED INC [US], et al
• See references of WO 03007798A2

Designated contracting state (EPC)
DE FR GB IT

DOCDB simple family (publication)
WO 03007798 A2 20030130; **WO 03007798 A3 20030619**; AU 2002316724 A1 20030303; EP 1418919 A2 20040519; EP 1418919 A4 20070613; JP 2004535462 A 20041125

DOCDB simple family (application)
US 0222860 W 20020719; AU 2002316724 A 20020719; EP 02747054 A 20020719; JP 2003513412 A 20020719